JX-929 was engineered from the same prototype as JX-963, targeting the epidermal growth factor (EGF)-receptor and ras signal transduction pathways. In this candidate, GM-CSF is replaced with cytosine deaminase. An IND has been filed with the US FDA in collaboration with Dr. David Bartlett at the University of Pittsburgh to pursue clinical development in lung, colon and ovarian cancers.